Patents by Inventor Robert J. Pelham
Robert J. Pelham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220396842Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.Type: ApplicationFiled: August 19, 2022Publication date: December 15, 2022Inventors: Steven SHAK, Frederick L. Baehner, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
-
Patent number: 11011252Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.Type: GrantFiled: May 2, 2017Date of Patent: May 18, 2021Assignee: Genomic Health, Inc.Inventors: Steven Shak, Mark Lee, William F. Novotny, Tara Maddala, Michael R. Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
-
Publication number: 20200263257Abstract: The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient. The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.Type: ApplicationFiled: February 7, 2020Publication date: August 20, 2020Applicant: GENOMIC HEALTH, INC.Inventors: Joffre B. BAKER, Dominick SINICROPI, Robert J. PELHAM, Michael R. CRAGER, Francois COLLIN, James C. STEPHANS, Mei-Lan LIU, John D. MORLAN, Kunbin QU
-
Publication number: 20200255911Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.Type: ApplicationFiled: February 25, 2020Publication date: August 13, 2020Applicant: GENOMIC HEALTH, INC.Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
-
Publication number: 20190256923Abstract: The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient. The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.Type: ApplicationFiled: January 17, 2019Publication date: August 22, 2019Applicant: GENOMIC HEALTH, INC.Inventors: Joffre B. BAKER, Dominick SINICROPI, Robert J. PELHAM, Michael R. CRAGER, Francois COLLIN, James C. STEPHANS, Mei-Lan LIU, John D. MORLAN, Kunbin QU
-
Publication number: 20190249260Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.Type: ApplicationFiled: February 22, 2019Publication date: August 15, 2019Applicant: GENOMIC HEALTH, INC.Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
-
Patent number: 10260104Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.Type: GrantFiled: October 20, 2015Date of Patent: April 16, 2019Assignee: Genomic Health, Inc.Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
-
Publication number: 20160222463Abstract: The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient, The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.Type: ApplicationFiled: January 29, 2016Publication date: August 4, 2016Applicant: GENOMIC HEALTH, INC.Inventors: Joffre B. BAKER, Dominick S. SINICROPI, Robert J. PELHAM, Michael R. CRAGER, Francois COLLIN, James C. STEPHANS, Mei-Lan LIU, John D. MORLAN, Kunbin QU
-
Publication number: 20160097105Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.Type: ApplicationFiled: October 20, 2015Publication date: April 7, 2016Applicant: GENOMIC HEALTH, INC.Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
-
Publication number: 20140303002Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.Type: ApplicationFiled: March 21, 2014Publication date: October 9, 2014Applicant: Genomic Health, Inc.Inventors: Steven Shak, Mark Lee, William F. Novotny, Tara Maddala, Michael R. Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
-
Publication number: 20140296085Abstract: The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient, The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.Type: ApplicationFiled: November 2, 2012Publication date: October 2, 2014Applicant: GENOMIC HEALTH, INC.Inventors: Joffre B. Baker, Dominick S. Sinicropi, Robert J. Pelham, Michael R. Crager, Francois Collin, James C. Stephans, Mei-Lan Liu, John D. Morlan, Kunbin Qu
-
Patent number: 8725426Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.Type: GrantFiled: January 28, 2013Date of Patent: May 13, 2014Assignee: Genomic Health, Inc.Inventors: Steve Shak, Mark Lee, William Novotny, Tara Maddala, Michael Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
-
Publication number: 20130274127Abstract: The present invention provides methods for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor. The methods generally involve determining an expression level of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. The present invention also provides methods for increasing sensitivity of a tumor cell to a PI3K inhibitor by contacting the tumor cell with an activator or inhibitor of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor.Type: ApplicationFiled: March 14, 2013Publication date: October 17, 2013Applicant: GENOMIC HEALTH, INC.Inventors: Joffre B. Baker, Robert J. Pelham, Kevin A. Kwei
-
Publication number: 20120046186Abstract: The present invention provides methods for predicting a likelihood that a patient with cancer will exhibit a positive response to a treatment with a platinum-based chemotherapy drug. The methods generally involve determining an expression level of a gene product that correlates with responsiveness to treatment with a platinum-based chemotherapy drug. In an embodiment of the invention, the platinum-based chemotherapy drug is oxaliplatin, and the cancer is colorectal cancer.Type: ApplicationFiled: August 16, 2011Publication date: February 23, 2012Inventors: ROBERT J. PELHAM, KELLY A. HARRADINE, JOFFRE B. BAKER
-
Publication number: 20120028264Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.Type: ApplicationFiled: July 25, 2011Publication date: February 2, 2012Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker